Park Square has placed David Woodhouse as Chief Executive Officer at Nuvig Therapeutics.
| less than a minute read
Nuvig Therapeutics Appoints David Woodhouse as CEO
Get in touch
Get in touch
Nuvig Therapeutics, Inc. (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced the appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and member of the Board of Directors and James Mackay, Ph.D., as Independent Board Chair.
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-04-15-32-04-091-6a7205f4b4306b41266d92f2.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-04-18-23-13-222-6a722e11663e81e26a6b2c3e.jpg)
